Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT02599922
PHASE1/PHASE2

Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)

Sponsor: Beacon Therapeutics

View on ClinicalTrials.gov

Summary

This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of AGTC-401 administered to one eye by subretinal injection in individuals with achromatopsia caused by mutations in the CNGB3 gene. The primary study endpoint will be safety and the secondary study endpoint will be efficacy.

Official title: A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene

Key Details

Gender

All

Age Range

4 Years - Any

Study Type

INTERVENTIONAL

Enrollment

32

Start Date

2016-04-11

Completion Date

2026-07

Last Updated

2022-07-22

Healthy Volunteers

No

Conditions

Interventions

BIOLOGICAL

rAAV2tYF-PR1.7-hCNGB3

rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.

Locations (8)

VitreoRetinal Associates

Gainesville, Florida, United States

Bascom Palmer Eye Institute

Miami, Florida, United States

Pangere Center for Inherited Retinal Diseases, The Chicago Lighthouse for People Who Are Blind or Visually Imp

Chicago, Illinois, United States

Massachusetts Eye and Ear Infirmary

Boston, Massachusetts, United States

Boston Children's Hospital

Boston, Massachusetts, United States

Duke Eye Center, Duke University Medical Center

Durham, North Carolina, United States

Cincinnati Eye Institute

Cincinnati, Ohio, United States

Casey Eye Institute, Oregon Health and Sciences University

Portland, Oregon, United States